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https://doi.org/10.1016/j.jacl.2019.10.0BACKGROUND: Alirocumab is a monoclonal antibody to proprotein convertase subtilisin/kexin type
9 (PCSK9).
OBJECTIVE: Changes in PCSK9, alirocumab, and low-density lipoprotein cholesterol (LDL-C)
levels were assessed after treatment with alirocumab at doses of 75 or 150 mg every 2 weeks (Q2W).
METHODS: Data were analyzed from 4 phase 3 trials (MONO; COMBO II; FH I; LONG TERM);
all but MONO enrolled patients on statins. Three trials evaluated alirocumab 75 mg Q2W, with
possible dose increase to 150 mg Q2W at week 12 based on week 8 LDL-C; LONG TERM studied
alirocumab 150 mg Q2W.
RESULTS: Patients on background statin therapy had higher mean baseline free PCSK9 concen-
trations vs patients not on statin. After alirocumab administration, increased alirocumab concen-
trations were associated with dramatic reductions in circulating free PCSK9, resulting in
significant LDL-C reductions and a corresponding increase in inactive PCSK9:alirocumab com-
plex. Alirocumab dose increase was associated with a further lowering of PCSK9 and LDL-C. Pa-
tients with higher baseline LDL-C levels (.160 mg/dL) were more likely to have their dose
increased. LDL-C reductions with alirocumab were consistent between patients with baseline
PCSK9 levels above or below the median when the dose increase strategy was used. When started
as alirocumab 150 mg Q2W, patients with PCSK9 levels above vs below the median had a greater
LDL-C reduction.f Iowa, 145 N. Riverside Dr, S455
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980 Journal of Clinical Lipidology, Vol 13, No 6, December 2019CONCLUSIONS: Alirocumab-induced changes in PCSK9 and LDL-C levels were consistent
with the known physiologic relationship between PCSK9, LDL receptor, and LDL-C levels, as
well as statin-induced increases in PCSK9 production.
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(LDL-C) are associated with increased cardiovascular (CV)
risk, and reduction in LDL-C by therapeutic means has
been demonstrated to reduce the risk of CVevents.1 LDL-C
is cleared from the circulation by LDL receptors on the sur-
face of hepatocytes. The number of available LDL recep-
tors is regulated by proprotein convertase subtilisin/kexin
type 9 (PCSK9), which promotes degradation of LDL re-
ceptors in the lysosome, thus limiting clearance of LDL-
C.2,3 Monoclonal antibodies that bind to and inhibit
PCSK9 lead to an increase in LDL receptor numbers and
hence a reduction in circulating LDL-C levels.3
Phase 1 and 2 clinical trials of the PCSK9 monoclonal
antibody alirocumab confirmed that levels of free PCSK9
(ie, that which is in the circulation and unbound to proteins)
are reduced by approximately 7 days after alirocumab
administration, corresponding to a marked reduction in
LDL-C.4–6 Levels of total PCSK9 (ie, all circulating
PCSK9 including free and protein-bound) were observed
to increase after alirocumab administration, representing
inactivated PCSK9 bound to alirocumab.
The initial trials in the alirocumab ODYSSEY phase 3
program7–15 utilized 2 dosing regimens, alirocumab 75 mg
every 2 weeks (Q2W), with possible dose increase to
150 mg Q2W depending on achievement of prespecified
LDL-C levels, or alirocumab 150 mg Q2W from the outset
(note that some later trials used every 4 weeks dosing reg-
imens).16,17 In a pooled analysis of 8 phase 3 studies, alir-
ocumab 75 mg Q2W (with possible dose increase to
150 mg Q2W at week 12) and alirocumab 150 mg Q2W
were shown to reduce LDL-C by 48.6%–60.5% (placebo
controls: 0.5%–4.2% increase; ezetimibe controls: 19.3%
reduction).18 However, changes in PCSK9 and alirocumab
levels corresponding to LDL-C changes in these phase 3 tri-
als, including data for the 75 mg dose and after dose in-
crease to 150 mg, have not been published. Here we
report available data from 4 phase 3 trials that included as-
sessments of alirocumab and PCSK9 levels.Methods
Studies and patients
This analysis includes 4 phase 3, randomized ODYS-
SEY trials in which PCSK9 and alirocumab concentrations
were measured in addition to LDL-C: MONO
(NCT01644474)7; COMBO II (NCT02023879)8; FH I
(NCT01623115)9; and LONG TERM (NCT01507831)10(Fig. 1). All patients had hypercholesterolemia, with base-
line LDL-C levels $70 mg/dL (in LONG TERM),
$100 mg/dL (in MONO), or $70/100 mg/dL (depending
on history of CV disease in FH I and COMBO II). FH I re-
cruited only patients with heterozygous familial hypercho-
lesterolemia (HeFH), COMBO II and MONO recruited
only patients with non-FH, and LONG TERM recruited pa-
tients with HeFH or non-FH. Except for MONO, which was
conducted without background statin therapy, all trials
enrolled patients who had been receiving maximally toler-
ated statin therapy for at least 4 weeks before study entry.
Other additional background lipid-lowering therapies (eg,
ezetimibe) were permitted in FH I and LONG TERM.
FH I and LONG TERM were placebo-controlled,
whereas MONO and COMBO II were ezetimibe-
controlled (Fig. 1). MONO, COMBO II, and FH I evaluated
alirocumab 75 mg Q2W, with a possible dose increase to
150 mg Q2W at week 12 if LDL-C remained $70 mg/dL
at week 8. LONG TERM evaluated alirocumab 150 mg
Q2W. Patients received alirocumab treatment for 24
(MONO), 78 (FH I and LONG TERM), or 104 weeks
(COMBO II). In all studies, alirocumab was administered
subcutaneously using a 1 mL prefilled autoinjector or pre-
filled syringe. Ezetimibe was given orally, at a daily dose
of 10 mg, with or without food (MONO and COMBO II).
The studies were performed in accordance with the ethical
principles in the Declaration of Helsinki, the International
Conference on Harmonization/Good Clinical Practice, and
appropriate local or regulatory requirements.
Endpoints and laboratory assessments
The primary efficacy endpoint of all trials was percent-
age change from the baseline in calculated LDL-C at week
24, analyzed in the intention-to-treat population, defined as
all randomized patients who had an evaluable primary
endpoint, in all 4 studies.
Blood samples were collected in the morning after a 10-
hour overnight fast and before study drug administration.
All lipid measurements and laboratory tests were assessed
by a central laboratory. LDL-C concentrations were
calculated using the Friedewald formula (LDL-C 5 total
cholesterol–HDL-C–[triglycerides/5], where all lipid con-
centrations are in mg/dL). However, if triglyceride values
were .400 mg/dL, LDL-C was determined by beta-
quantification (such values were not included in the present
analysis). Serum samples for total alirocumab and PCSK9
concentrations were collected before dose at week
0 (randomization visit), weeks 4, 12, 16, and 24, and at
Figure 1 ODYSSEY phase 3 studies and patient populations included in this analysis. Clinicaltrials.gov identifiers: NCT01644474
(MONO); NCT01623115 (FH I); NCT02023879 (COMBO II); NCT01507831 (LONG TERM). CV, cardiovascular; HeFH, heterozygous
familial hypercholesterolemia; ITT, intention-to-treat; Q2W, every 2 wk.
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study, where samples were collected at weeks 4, 8, 12,
and 16, and during follow-up.
Concentrations of alirocumab and total and free PCSK9
were determined by enzyme-linked immunosorbent assay.
The method for determining alirocumab concentration
included an acid treatment step to dissociate soluble
PCSK9:drug complexes present in serum. Alirocumab
captured on plates coated with PCSK9 was detected using
a mouse anti-alirocumab mAb, followed by a horseradish
peroxidase (HRP)-conjugated goat anti-mouse IgG, Fcg
subclass 2b–specific, polyclonal antibody (goat anti-mouse-
IgG2b-HRP). A luminol-based substrate specific for perox-
idase was then added to achieve a signal. This assay has a
lower limit of quantification (LLOQ) of 0.078 mg/mL in
undiluted serum. Alirocumab concentrations presented are
trough concentrations (assessed 8–21 days after previous
injection).
To quantitate free PCSK9 and minimize dissociation of
the PCSK9:alirocumab complex in the sample, the assay
used a low-affinity anti-PCSK9 mAb, specific for the
catalytic domain of PCSK9 as the capture reagent, reduced
incubation times, and decreased sample dilution. Standards
were prepared in and samples were diluted with PCSK9-
depleted human serum. Free PCSK9 captured on the plate
was detected using a biotinylated mouse anti-PCSK9 mAb,
specific for the pro domain of PCSK9, followed by
neutrAvidin-HRP. A luminol-based substrate specific for
peroxidase was added to generate a chemiluminescent
signal. This assay has an LLOQ of 0.031 mg/mL in
undiluted serum.
For total PCSK9 also, standards were prepared in and
samples were diluted with PCSK9-depleted human serum.
The assay used an acid treatment of the serum samples and
standards to dissociate any complexed PCSK9, includingany PCSK9:alirocumab complexes that might be present in
the serum. The acidified sample was neutralized and all
dissociated PCSK9 was captured on a microtiter plate
coated with a high-affinity, anti-PCSK9 mAb. PCSK9
captured on the plate was detected using a biotinylated
mouse anti-PCSK9 mAb, which noncompetitively bound to
PCSK9, followed by neutravidin-HRP. A luminol-based
substrate specific for peroxidase was then added to generate
a chemiluminescent signal. This assay has an LLOQ of
0.156 mg/mL in undiluted serum.
Treatment emergent adverse events (TEAEs) were
defined as AEs that, irrespective of relationship to study
drug, developed or worsened or became serious between
the first to last injection plus 70 days.
Statistical considerations
Alirocumab, free PCSK9, and total PCSK9 analyses
were performed in randomized and treated patients (safety
population) with at least 1 evaluable sample after the first
injection. Safety analyses were performed on the safety
population, defined as all randomized patients who received
at least 1 dose or part of a dose of the study drug. Safety
data for FH I and LONG TERM (alirocumab vs placebo) as
well as those for MONO and COMBO II (alirocumab vs
ezetimibe) were pooled for the purposes of this analysis.
Percentage change in LDL-C was assessed using mixed
effect models for repeated measures to account for missing
values.7 LDL-C concentrations up to week 24 are presented
for the intention-to-treat population. Comparison of LDL-C
reductions at week 24 for alirocumab vs control according
to baseline PCSK9 levels and statin dose intensity were
conducted using the mixed effect models for repeated mea-
sures. Wilcoxon tests were used to compare baseline
PCSK9 levels between groups. No other statistical
982 Journal of Clinical Lipidology, Vol 13, No 6, December 2019comparisons were performed, and data are summarized
descriptively.Results
Patient disposition and baseline characteristics
Across the 4 studies, 3650 patients were randomized
(Fig. 1), 2407 to alirocumab arms. Pharmacokinetic samples
were collected in 2360 patients randomized to alirocumab.
Baseline characteristics for each trial are shown in
Supplementary Table 1. Mean age was 51.9–61.6 years
and mean body mass index was 29.3–30.3 kg/m2. The pro-
portion of male patients varied across the studies. The pro-
portion of patients with ASCVD was 95.1% (COMBO II),
48.4% (FH I), and 76.8% (LONG TERM; no patients had
ASCVD in MONO); the proportions with FH were 0%
for COMBO II and MONO, 100% for FH I, and 18% for
LONG TERM.
Baseline PCSK9 levels are shown in Table 1. In patients
on background statin therapy (pooled FH I, COMBO II, and
LONG TERM studies), median baseline free and total
PCSK9 concentrations were higher (286.0 ng/mL and
647.0 ng/mL, respectively) than those not on background
statin from the MONO study (181.5 ng/mL and 475.0 ng/
mL, respectively; all P , .0001). Furthermore, baseline
PCSK9 levels were notably higher in FH I (which included
only patients with FH) compared with the other studies.
Patients who received an alirocumab dose increase from
75 mg Q2W to 150 mg Q2W at week 12 had higher mean
LDL-C at the baseline compared with patients who
remained on 75 mg Q2W (MONO: 153.2 vs 134.7 mg/
dL; COMBO II: 140.4 vs 101.1 mg/dL; FH I: 164.9 vs
130.1 mg/dL; Table 2). Most patients who had their doseTable 1 Baseline PCSK9 levels
Parameter
COMBO II
(n 5 695)
Studies on background statins
FH I
(n 5 479)
LONG TERM
(n 5 2301)
Baseline free PCSK9
levels (ng/mL)
Number 670 467 2226
Mean (SD) 283.1 (98.8) 314.7 (128.0) 305.0 (121.
Median 275.5 292.0 289.0
Q1: Q3 216.0: 340.0 228.0: 392.0 219.0: 375.
Min: Max 0: 704 0: 819 0: 1040
Baseline total PCSK9
levels (ng/mL)
Number 671 467 2226
Mean (SD) 620.6 (187.4) 853.6 (293.1) 679.1 (298.
Median 592.0 821.0 637.0
Q1: Q3 492.0: 729.0 637.0: 1040.0 504.0: 805.
Min: Max 175: 1430 0: 2040 213: 9030
PCSK9, proprotein convertase subtilisin/kexin type 9; SD, standard deviatio
Note: P-value from Wilcoxon test. Bold represents median PCSK9 values inincreased had baseline LDL-C levels .160 mg/dL
(Supplementary Table 2). However, baseline free PCSK9
levels were only slightly higher in patients who received
dose increase vs no dose increase in MONO and COMBO
II and were similar regardless of whether dose was
increased in FH I (Table 2).
Changes in LDL-C, free PCSK9, and alirocumab
Changes over time for alirocumab, free PCSK9, and
LDL-C for alirocumab-treated patients in the MONO,
COMBO II, and LONG TERM studies are shown in
Figure 2 (data for FH I are shown in Supplementary
Fig. 1). In all studies, by week 4, alirocumab concentrations
had increased and free PCSK9 concentrations had reduced,
with corresponding marked reductions in LDL-C. LDL-C
changes from the baseline to week 24 with alirocumab vs
controls were significant (P , .0001) in all the trials. Re-
ductions in free PCSK9 and LDL-C were maintained
throughout each study. The reductions in free PCSK9 and
increases in alirocumab levels also corresponded with in-
creases in the inactive PCSK9:alirocumab complex (repre-
sented by total PCSK9; Supplementary Fig. 2).
Treatment with alirocumab 150 mg Q2W in the LONG
TERM trial resulted in lower free PCSK9 concentrations
(range 42.5–56.8 ng/mL from weeks 4–12) vs the other
trials performed with background statin in which all
patients were receiving alirocumab 75 mg Q2W up to
week 12 (ranges: 118.9–186.1 ng/mL for FH I and 108.2–
154.6 ng/mL for COMBO II, from weeks 4–12). Free
PCSK9 levels in MONO (no background statin) from
weeks 4 to 12 were the lowest of the 4 studies, ranging
from 14.9 to 46.1 ng/mL.
LDL-C reductions with alirocumab were consistent
between patients with baseline free PCSK9 levels at/abovePool
(n 5 3475)
Studies without statins P-value
MONO (n 5 103)
Studies with vs
without statins
,.0001
3363 102
5) 302.0 (118.7) 185.5 (56.4)
286.0 181.5
0 220.0: 371.0 148.0: 214.0
0: 1040 0: 324
,.0001
3364 103
8) 691.6 (287.6) 497.5 (154.4)
647.0 475.0
0 514.0: 820.0 391.0: 594.0
0: 9030 204: 936
n.
patients receiving or not receiving statin therapy.
Table 2 Free PCSK9 and LDL-C levels by dose increase status*
Study MONO COMBO II FH I
Patients with dose increase, n/N (%) 14/46 (30.4) 82/446 (18.4) 135/311 (43.4)
Baseline free PCSK9, mean (SD), ng/mL
Patients with dose increase 213.8 (38.3) 295.2 (106.5) 312.5 (144.7)
Patients without dose increase 178.4 (53.6) 271.5 (93.9) 316.5 (120.7)
Baseline LDL-C, mean (SD), mg/dL
Patients with dose increase 153.2 (24.6) 140.4 (47.4) 164.9 (55.1)
Patients without dose increase 134.7 (26.7) 101.1 (29.7) 130.1 (42.5)
Additional % LDL-C reduction from week 12 to
week 24, mean (SD)
21.4% (8.9) 210.5% (32.6) 215.1% (23.8)
LDL-C, low-density lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9; Q2W, every 2 weeks; SD, standard deviation.
*Alirocumab dose increased from 75 to 150 mg Q2W at week 12 if week 8 LDL-C was $70 mg/dL. LONG TERM not included as dose increase was not
possible in that study.
Figure 2 Mean concentrations of alirocumab, free PCSK9, and LDL-C over time in patients receiving (A) alirocumab 75/150 mg Q2W
without background statin (MONO); (B) alirocumab 75/150 mg Q2W with background statin (COMBO II); and (C) alirocumab 150 mg
Q2W with background statin (LONG TERM). Alirocumab 75/150 mg refers to studies where the starting dose of 75 mg was increased to
150 mg at study week 12 if week 8 LDL-C was$70 mg/dL. Alirocumab and PCSK9 samples were available only up to 16 weeks in LONG
TERM. LDL-C, low-density lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9; Q2W, every 2 wk; SE, standard
error.
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strategy was used. When started as the alirocumab 150 mg
Q2W dose in LONG TERM, patients with PCSK9 levels at/
above the median had a greater LDL-C reduction compared
with those below the median (interaction P-value 5 .0076)
(Fig. 3). As the interaction P-values were calculated using
the difference in LDL-C percentage reduction for alirocu-
mab vs control, the LDL-C changes in the placebo group
(20.5% and 12.9% for patients with baseline free
PCSK9 below or at/above the median) can at least partially
account for the significant interaction P-value seen in the
LONG TERM study. The LDL-C changes in the alirocu-
mab group in LONG TERM were 259.4% and 262.8%
for patients with free PCSK9 below or at/above the median.
Similar results were observed when analyzed by quartiles
of baseline total PCSK9 levels (Supplementary Fig. 3).
Effect of alirocumab dose increase
The proportion of patients who had their dose increased
is shown in Table 2. Changes in alirocumab, PCSK9, and
LDL-C levels after dose increase are shown for the
MONO study in Figure 4 and for COMBO II and FH I in
Supplementary Figures 4 and 5, respectively. Mean concen-
trations of alirocumab increased in an approximately dose-
proportional or slightly greater than dose-proportional
manner when alirocumab dose was increased from 75 mg
Q2W to 150 mg Q2W.
Similar to the pattern seen at the baseline, at week 12
(before potential dose increase), mean free PCSK9 levels in
MONO and COMBO II were somewhat higher in patients
who had the dose increase vs no dose increase (59.3 vs
40.4 ng/mL [MONO]; 211.9 vs 141.5 ng/mL [COMBO II],
respectively). At week 24, mean free PCSK9 levels decreased
further (compared with week 12) in patients who had the dose
increase to 14.3 ng/mL in MONO and 131.3 ng/mL in
COMBO II (week 24 free PCSK9 levels in patients with noFigure 3 LDL-C percentage reduction at week 24 according to baselin
interval; LDL-C, low-density lipoprotein cholesterol; LS, least squares;
2 wk; SE, standard error.dose increase were 36.9 and 136.7 ng/mL in MONO and
COMBO II, respectively). In FH I, mean free PCSK9 levels at
week 12 were comparable for patients who received the dose
increase vs no dose increase (188.9 vs 185.5 ng/mL) although
levels were further reduced to 80.5 ng/mL at week 24 in
patients who had the dose increase (compared with 165.9 ng/
mL for patients with no dose increase).
The further reductions in free PCSK9 levels after
alirocumab dose increase corresponded with additional
percentage reductions in LDL-C (week 24 compared with
week 12) of 10.5% and 15.1% in the trials with
background statins (COMBO II and FH I, respectively);
in MONO (no statins), the additional percentage LDL-C
reduction was 1.4% (Table 2). At week 24, percentage
LDL-C reductions from the baseline in patients with and
without dose increase were, respectively, 50.6% and
55.5% in MONO, 42.5% and 54.7% in COMBO II, and
51.5% and 48.9% in FH I. Reductions in week 24 LDL-
C ranged from 42.5%–51.5% for those with a dose in-
crease and 48.9%–55.5% for those who remained on
75 mg Q2W.
Effect of statin dose intensity on PCSK9 levels
and LDL-C reductions
As noted previously, baseline free and total PCSK9
levels were higher in patients who were receiving a statin vs
no statin. We also examined levels of free and total PCSK9
over time according to baseline statin intensity
(Supplementary Figs. 6–8). Across the three studies that
included patients on background statins, both free and total
PCSK9 levels were consistently higher over the course of
the studies in patients who were receiving high-intensity
statin vs no high-intensity statin. However, we did not
find any differences in terms of LDL-C reductions when
comparing groups who were receiving high-intensity statin
vs no high-intensity statin (Supplementary Fig. 9).e free PCSK9 levels below or at/above the median. CI, confidence
PCSK9, proprotein convertase subtilisin/kexin type 9; Q2W, every
Robinson et al PCSK9 and LDL-C with alirocumab 985Safety analyses
Pooled safety data from the four studies are shown in
Supplementary Table 3. The rates of TEAEs, treatment-
emergent serious AEs, and TEAEs leading to discontinuations
or deaths were generally similar between alirocumab and con-
trol arms. The most frequently reported TEAEs included na-
sopharyngitis, accidental overdose, upper respiratory tract
infection, dizziness, and injection site reaction. TEAEs were
generally comparable between alirocumab and control arms,
with the exception of a higher rate of injection site reactions
with alirocumab. Most injection site reactions, however,
were mild in severity. Safety data were also compared be-
tween alirocumab and control groups with baseline total
PCSK9 levels below or at/above the median (Fig. 5), apartFigure 4 Effect of alirocumab dose increase from 75 to 150 mg Q2Wo
LDL-C over time, in alirocumab-treated patients from the MONO stud
terol; PCSK9, proprotein convertase subtilisin/kexin type 9; Q2W, everfrom a few small differences between groups (eg, injection
site reactions occurred in 4.6% and 7.5% of alirocumab-
treated patients with baseline total PCSK9 levels below or
at/above the median, respectively) there was no clear pattern
according to baseline total PCSK9 levels.
Discussion
After administration of alirocumab 75 or 150 mg Q2W
in the 4 phase 3 trials included in this analysis, increased
alirocumab concentrations corresponded with a sharp
decrease in free PCSK9 concentrations and an associated
significant decrease in LDL-C. These changes were seen by
week 4 and sustained through the course of the studies, and
results were consistent among patients with HeFH and non-n mean concentrations of (A) alirocumab, (B) free PCSK9 and (C)
y (no background statin). LDL-C, low-density lipoprotein choles-
y 2 wk; SE, standard error; W, week.
Figure 5 Adverse events by baseline total PCSK9 levels below or at/above the median. Pooled data from LONG TERM, COMBO II, FH
I, and MONO studies. Total number of patients per group: alirocumab, below median, N 5 1147, at/above median, N 5 1170; control,
below median N 5 609, at/above median N 5 590. TEAE, treatment-emergent adverse event.
986 Journal of Clinical Lipidology, Vol 13, No 6, December 2019FH. There was a corresponding increase in total PCSK9
levels reflecting increased levels of the inactive PCSK9:a-
lirocumab complex. These results confirm those of alir-
ocumab phase 1 and 2 trials4–6; however, the present
analysis is the first to report pharmacokinetic and PCSK9
data for the 75 mg Q2W dose and following dose increase
to 150 mg Q2W. As seen in previous studies, total PCSK9
levels were higher at the baseline compared with free
PCSK9 levels; however, it is not clear what endogenous el-
ements may be binding PCSK9 in serum. After alirocumab
administration, all but the most insignificant amount of to-
tal PCSK9, not accounted for by the free PCSK9 assay, is
bound to alirocumab. The difference between free and total
PCSK9 at the baseline is not currently well understood.
Three of the trials in this analysis allowed for alirocu-
mab dose increase at week 12 based on week 8 LDL-C.7–9
Dose increase was associated with a further reduction in
free PCSK9 levels and a corresponding further reduction
in LDL-C; however, the additional LDL-C reduction afterdose increase in MONO was relatively small compared
with FH I and COMBO II. One explanation for this may
be the lower baseline PCSK9 levels observed in patients
from MONO, who were not receiving background statin
therapy, compared with the other studies in which patients
were receiving background maximally tolerated statin. The
higher levels of PCSK9 in the statin-treated patients may be
accounted for by the statin-induced increased production of
PCSK9 via upregulation of sterol-responsive element-bind-
ing protein 2.2 If most of the free PCSK9 is already bound
to alirocumab in patients receiving the 75 mg Q2W dose
(ie, the system is fully saturated), this could explain why
increasing the alirocumab dose had only minimal effects
on LDL-C in the patients not on statin from MONO. How-
ever, the efficacy of alirocumab was found to be consistent
in patients with baseline free PCSK9 above or below the
median. In MONO and COMBO II, patients with dose in-
crease had a lower percentage LDL-C reduction at week
24 compared with patients with no dose increase. An
Robinson et al PCSK9 and LDL-C with alirocumab 987explanation for this is that patients with a lower percentage
reduction were more likely to not reach the LDL-C goal at
week 8 and therefore were more likely to have their dose
increased (in FH I, percent reductions were similar at
week 24 regardless of dose increase status).
Baseline LDL-C levels were higher in patients who
required alirocumab dose increase (vs no dose increase) in
all studies, in agreement with previous analyses showing
that baseline LDL-C levels are the main determining factor
for requiring alirocumab dose increase.19 Overall, 51.2% of
patients from MONO, COMBO II, and FH I with baseline
LDL-C $130 mg/dL received a dose increase. Baseline
free PCSK9 levels were also somewhat higher in patients
who required dose increase (vs no dose increase) in
MONO and COMBO II, although this was not true for
FH I. However, baseline PCSK9 levels were highest overall
in FH I vs the other trials, in agreement with previous re-
ports of elevated PCSK9 levels in patients with FH.20
There have been some reports of resistance to PCSK9
mAbs. In one study, two patients with FH (confirmed by
clinical criteria) were reported to have a lack of LDL-C
response, either despite an increase in total PCSK9 levels
(suggesting alirocumab had bound to PCSK9 in the circu-
lation) or with a lack of increase in total PCSK9 (that may
suggest lack of alirocumab binding to PCSK9 or that
alirocumab did not enter the circulation in sufficient
levels).21 In an analysis of patients who participated in alir-
ocumab ODYSSEY trials, a small number of patients ran-
domized to alirocumab (,1%) who had ,15% LDL-C
reduction were identified, but in most of these patients,
nonadherence was felt to explain the lack of response.22
For a few patients with lack of response, alirocumab receipt
was confirmed by PK analysis, with a corresponding
decrease in free PCSK9 and an increase in total PCSK9.
Such cases may suggest a mutation or mutations in the
LDLR and/or APOB genes that reduce uptake of LDL-C
from the circulation (thus interfering with the mode of ac-
tion of PCSK9 inhibition with alirocumab). In some of the
patients with lack of LDL-C response in the ODYSSEY tri-
als, LDLR mutations were identified; however, other pa-
tients with the same mutations did show a response.22 A
further analysis of genetically profiled patients with either
double or compound heterozygous LDLR and/or APOB mu-
tations found that the LDL-C response (reduction from
baseline) ranged from 8.8% to 65.1% with alirocumab.23
In the trials included in this analysis, alirocumab was
generally well tolerated with safety comparable with
controls (except for a higher frequency of injection site
reactions with alirocumab). These results are in agreement
with a pooled safety analysis of alirocumab phase 2 and 3
trials as well as results from the ODYSSEY OUTCOMES
CV outcomes trial.24,25
In summary, alirocumab-induced changes in PCSK9 and
LDL-C concentrations in this analysis were consistent with
the known physiologic relationship between concentrations
of PCSK9, LDL receptor, and LDL-C, as well as statin-
induced increases in PCSK9 production. Taken together,these analyses provide further support for the use of
alirocumab 75 mg Q2W and dose increase to 150 mg
Q2W (based on LDL-C levels) as efficacious dosing
regimens for clinically meaningful LDL-C reductions in
patients with hypercholesterolemia receiving maximally
tolerated statin therapy.
Acknowledgments
The authors would like to thank study individuals and
investigators, and the following persons from sponsors for
their contributions to data collection and analysis, assis-
tance with statistical analysis, or critical review of the
manuscript: Regeneron: Eva-Lynne Greene, Carol Hudson,
Rita Samuel, Desmond Thompson; Sanofi: Corinne Han-
otin, Michael Howard, L. Veronica Lee, Guillaume Le-
corps, Laurence Merlet, Christelle Lorenzato, and Jonas
Mandel. This analysis was funded by Sanofi and Regeneron
Pharmaceuticals, Inc. Medical writing support was pro-
vided by Rachel Wright, PhD, and Susanne Ulm, PhD, of
Prime (Knutsford, UK), funded by Sanofi and Regeneron
Pharmaceuticals Inc according to Good Publication Prac-
tice guidelines (http://annals.org/aim/article/2424869/good-
publication-practice-communicating-company-sponsored-
medical-research-gpp3). The Sponsor was involved in the
study design, collection, analysis, and interpretation of
data, as well as data checking of information provided in
the manuscript. The authors had unrestricted access to
data, were responsible for all content and editorial deci-
sions, and received no honoraria related to the development
of this publication.
Authors’ contributions: J.G.R., M. F., J.J.P.K., H.M.C.,
and C.P.C. contributed to study design or concept, data
acquisition, analysis and interpretation of the data, and crit-
ically reviewed and edited the manuscript. E.M.R. and M.-
R.T. contributed to data acquisition, analysis and interpreta-
tion of the data, and critically reviewed and edited the
manuscript. A.B., A.T.DC, R.P., and M.T.B.-D. contributed
to study design or concept, analysis, and interpretation of
the data, and critically reviewed and edited the manuscript.
G.L. contributed to analysis and interpretation of the data,
and critically reviewed and edited the manuscript. All au-
thors approved the final version.Financial Disclosure
J.G.R has received consultant fees from Amgen, Merck,
Novartis, Novo Nordisk, Pfizer, Regeneron, and Sanofi; and
research grants to her institution from Acasti, Amarin,
Amgen, AstraZeneca, Eisai, Esperion, Eli Lilly, Merck,
Novartis, Novo Nordisk, Pfizer, Regeneron, Sanofi and
Takeda. M.F. has received research support from Sanofi/
Regeneron Pharmaceuticals, Inc, Amgen and Merck and
Co; has served as a consultant for Sanofi/Regeneron
Pharmaceuticals, Inc, Pfizer, Amgen, Merck and Co, Eli
Lilly, AstraZeneca, Kowa, Akcea/Ionis, Amarin, Servier,
988 Journal of Clinical Lipidology, Vol 13, No 6, December 2019and Daichii-Sankyo; and has received speaker fees from
Sanofi/Regeneron Pharmaceuticals, Inc, Abbott, Amgen,
Merck and Co, Pfizer, and Mylan. J.J.P.K. has received
honoraria from Dezima Pharmaceuticals, Regeneron, Sa-
nofi, Eli Lilly, Pfizer, Amgen, Aegerion, Esperion, Ionis,
Cymabay, and Gemphire; and consultant/advisory board
fees from Dezima Pharmaceuticals, Regeneron, Sanofi, Eli
Lilly, Pfizer, Amgen, Aegerion, Esperion, Ionis, Cymabay,
and Gemphire. E.M.R. is employed by a company that has
received research funds and consulting fees from Regen-
eron, Sanofi, and Amgen. M.-R.T. is consultant for or has
received honoraria from Amgen, AstraZeneca, Chiesi,
Novo Nordisk, and Sanofi Aventis. H.N.G. has received
research grants from Amgen, Merck, Sanofi, and Regen-
eron Pharmaceuticals, Inc; and is a consultant on advisory
boards for Amgen, Janssen, Lilly, Merck, Novartis, Re-
serlogix, Sanofi, and Regeneron Pharmaceuticals, Inc.
H.M.C. has received grants, personal fees, and nonfinancial
support from Sanofi and Regeneron Pharmaceuticals, Inc;
grants, institutional fees, and non-financial support from Eli
Lilly and Company; grants from AstraZeneca and Pfizer
Inc; and grants and fees from Novo Nordisk; and owns
stock in Roche Pharmaceuticals and Bayer. A.B., G.L. and
M.T.B.-D. are employees and stockholders of Sanofi.
A.T.D. and R.P. are employees and stockholders of
Regeneron Pharmaceuticals Inc. C.P.C. has received
research grants from Amgen, Boehringer Ingelheim,
Bristol-Myers Squibb, Daiichi Sankyo, Janssen, Merck;
and consulting fees from Alnylam, Amarin, Amgen,
Boehringer Ingelheim, Bristol-Myers Squibb, Eisai Co,
Janssen, Kowa, Merck, Pfizer, Regeneron Pharmaceuticals,
Inc, and Sanofi.References
1. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACV-
PR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guide-
line on the Management of Blood Cholesterol. Circulation. 2018;
139:e1082–e1143.
2. Guo YL, Zhang W, Li JJ. PCSK9 and lipid lowering drugs. Clin Chim
Acta. 2014;437:66–71.
3. McKenney JM. Understanding PCSK9 and anti-PCSK9 therapies. J
Clin Lipidol. 2015;9:170–186.
4. Rey J, Poitiers F, Paehler T, et al. Relationship between low-density
lipoprotein cholesterol, free proprotein convertase subtilisin/kexin
type 9, and alirocumab levels after different lipid-lowering strategies.
J Am Heart Assoc. 2016;5:e003323.
5. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin
with or without an antibody to PCSK9 in primary hypercholesterole-
mia. N Engl J Med. 2012;367:1891–1900.
6. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal
antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366:
1108–1118.
7. Roth EM, Taskinen MR, Ginsberg HN, et al. Monotherapy with the
PCSK9 inhibitor alirocumab versus ezetimibe in patients with hyper-
cholesterolemia: results of a 24 week, double-blind, randomized Phase
3 trial. Int J Cardiol. 2014;176:55–61.
8. Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of alirocu-
mab in high cardiovascular risk patients with inadequately controlled
hypercholesterolaemia on maximally tolerated doses of statins: theODYSSEY COMBO II randomized controlled trial. Eur Heart J.
2015;36:1186–1194.
9. Kastelein JJP, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and
FH II: 78 week results with alirocumab treatment in 735 patients
with heterozygous familial hypercholesterolaemia. Eur Heart J.
2015;36:2996–3003.
10. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alir-
ocumab in reducing lipids and cardiovascular events. N Engl J Med.
2015;372:1489–1499.
11. Moriarty PM, Jacobson TA, Bruckert E, et al. Efficacy and safety of
alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant pa-
tients: design and rationale of ODYSSEYALTERNATIVE, a random-
ized phase 3 trial. J Clin Lipidol. 2014;8:554–561.
12. Ginsberg HN, Rader DJ, Raal FJ, et al. Efficacy and safety of alirocu-
mab in patients with heterozygous familial hypercholesterolemia and
LDL-C of 160 mg/dl or higher. Cardiovasc Drugs Ther. 2016;30:
473–483.
13. Bays H, Gaudet D, Weiss R, et al. Alirocumab as add-on to atorvasta-
tin versus other lipid treatment strategies: ODYSSEY OPTIONS I ran-
domized trial. J Clin Endocrinol Metab. 2015;100:3140–3148.
14. Farnier M, Jones P, Severance R, et al. Efficacy and safety of adding
alirocumab to rosuvastatin versus adding ezetimibe or doubling the ro-
suvastatin dose in high cardiovascular-risk patients: the ODYSSEY
OPTIONS II randomized trial. Atherosclerosis. 2016;244:138–146.
15. Kereiakes DJ, Robinson JG, Cannon CP, et al. Efficacy and safety of
the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab
among high cardiovascular risk patients on maximally tolerated statin
therapy: the ODYSSEY COMBO I study. Am Heart J. 2015;169:
906–915.e13.
16. Stroes E, Guyton JR, Lepor N, et al. Efficacy and safety of alirocumab
150 mg every 4 weeks in patients with hypercholesterolemia not on
statin therapy: the ODYSSEY CHOICE II study. J Am Heart Assoc.
2016;5:e003421.
17. Roth EM, Moriarty PM, Bergeron J, et al. A phase III randomized trial
evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-
on to statin: ODYSSEY CHOICE I. Atherosclerosis. 2016;254:
254–262.
18. Farnier M, Gaudet D, Valcheva V, Minini P, Miller K, Cariou B. Effi-
cacy of alirocumab in high cardiovascular risk populations with or
without heterozygous familial hypercholesterolemia: pooled analysis
of eight ODYSSEY Phase 3 clinical program trials. Int J Cardiol.
2016;223:750–757.
19. Kastelein JJ, Kereiakes DJ, Cannon CP, et al. Effect of alirocumab
dose increase on LDL lowering and lipid goal attainment in patients
with dyslipidemia. Coron Artery Dis. 2017;28:190–197.
20. Raal F, Panz V, Immelman A, Pilcher G. Elevated PCSK9 levels in un-
treated patients with heterozygous or homozygous familial hypercho-
lesterolemia and the response to high-dose statin therapy. J Am Heart
Assoc. 2013;2:e000028.
21. Shapiro MD, Miles J, Tavori H, Fazio S. Diagnosing resistance to a
proprotein convertase Subtilisin/Kexin type 9 inhibitor. Ann Intern
Med. 2018;168:376–379.
22. Bays HE, Rosenson RS, Baccara-Dinet MT, Louie MJ, Thompson D,
Hovingh GK. Assessment of the 1% of patients with consistent ,15%
reduction in low-density lipoprotein cholesterol: pooled analysis of 10
phase 3 ODYSSEY alirocumab trials. Cardiovasc Drugs Ther. 2018;
32:175–180.
23. Hartgers ML, Defesche JC, Langslet G, et al. Alirocumab efficacy in
patients with double heterozygous, compound heterozygous, or homo-
zygous familial hypercholesterolemia. J Clin Lipidol. 2018;12:
390–396.e8.
24. Jones PH, Bays HE, Chaudhari U, et al. Safety of alirocumab (a
PCSK9 monoclonal antibody) from 14 randomized trials. Am J Car-
diol. 2016;118:1805–1811.
25. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascu-
lar outcomes after acute coronary syndrome. N Engl J Med. 2018;379:
2097–2107.
Robinson et al PCSK9 and LDL-C with alirocumab 988.e1AppendixSupplementary Table 1 Study and baseline characteristics (randomized population)
MONO (n 5 103) COMBO II (n 5 720) FH I (n 5 486) LONG TERM (n 5 2341)
Patient characteristics at the baseline
Mean age, years (SD) 60.2 (5.0) 61.6 (9.3) 51.9 (12.7) 60.5 (10.4)
Male gender, n (%) 55 (53.4) 530 (73.6) 274 (56.4) 1457 (62.2)
Race/ethnicity white, n (%) 93 (90.3) 610 (84.7) 444 (91.4) 2171 (92.7)
Mean BMI (SD) 29.3 (6.3) 30.1 (5.3) 29.3 (4.9) 30.3 (5.6)
ASCVD, n (%) 0 685 (95.1) 235 (48.4) 1799 (76.8)
CHD, n (%) N/A 649 (90.1) 225 (46.3) 1607 (68.6)
CHD associated with .1 comorbidity*
or CVD†
N/A 544 (75.6) 147 (30.2) 1294 (55.3)
CHD risk equivalents‡ N/A 233 (31.0) 79 (16.3) 962 (41.1)
Mean SCORE (SD)x 2.8 (1.2) N/A N/A N/A
Familial hypercholesterolemia, n (%) 0 0 486 (100) 415 (17.7)
High-intensity statink, n (%) 0 480 (66.7) 396 (81.5) 1032 (44.1)
Non-statin LLT, n (%) 5 (4.9) 41 (5.7){ 305 (62.8){ 657 (28.1){
Mean LDL-C, mg/dL (SD) 139.7 (25.8) 107.3 (35.7) 144.6 (49.7) 122.4 (42.2)
ALI, alirocumab; ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; CHD, coronary heart disease; CVD, cardiovascular disease; EZE,
ezetimibe; LDL-C, low-density lipoprotein cholesterol; LLT, lipid lowering therapy; N/A, not applicable; PBO, placebo; PCSK9, proprotein convertase
subtilisin/kexin type 9; SCORE, Systematic Coronary Risk Estimation; SD, standard deviation.
*Comorbidity includes hypertension, diabetes or moderate chronic kidney disease.
†CVD includes ischemic stroke and peripheral arterial disease.
‡Includes ischemic stroke, peripheral arterial disease, moderate chronic kidney disease, known history of diabetes and (2) additional risk factors.
xMONO study excluded patients with CHD. Only those with moderate CV risk, as assessed using Systematic Coronary Risk Estimation (SCORE), were
included.
kDefined as atorvastatin 40 to 80 mg daily or rosuvastatin 20 to 40 mg daily.
{With or without statin.Supplementary Table 2 Alirocumab dose adjustment status at week 12 according to baseline calculated LDL-C levels (ITT population;
pool of alirocumab-treated patients from MONO, COMBO II, and FH I)
n (%)
Calculated LDL-C at the baseline
#100 mg/dL $100 to ,130 mg/dL $130 to ,160 mg/dL $160 mg/dL
N n 5 268 n 5 232 n 5 165 n 5 138
Dose adjustment from 75 mg Q2W to 150 mg
Q2W at week 12
24 (9.0) 52 (22.4) 68 (41.2) 87 (63.0)
ITT, intention-to-treat; LDL-C, low-density lipoprotein cholesterol; Q2W, every 2 wk.
Patients who prematurely discontinued the study treatment before week 12 are excluded from this analysis.
Supplementary Table 3 Safety summary (safety population)
Values are n (%)
Placebo-controlled trials
Pool of FH I and LONG TERM
Ezetimibe-controlled trials
Pool of COMBO II and MONO
Alirocumab (n 5 1872) Placebo (n 5 951) Alirocumab (n 5 531) Ezetimibe (n 5 292)
TEAEs 1518 (81.1) 779 (81.9) 427 (80.4) 238 (81.5)
Treatment-emergent SAEs 334 (17.8) 176 (18.5) 125 (23.5) 61 (20.9)
TEAEs leading to death 14 (0.7) 10 (1.1) 6 (1.1) 6 (2.1)
TEAEs leading to discontinuation 122 (6.5) 56 (5.9) 49 (9.2) 23 (7.9)
TEAEs in $5% of patients
Nasopharyngitis 245 (13.1) 115 (12.1) 35 (6.6) 23 (7.9)
Upper respiratory tract infection 137 (7.3) 82 (8.6) 44 (8.3) 22 (7.5)
Injection site reaction 131 (7.0) 51 (5.4) 13 (2.4) 5 (1.7)
Influenza 108 (5.8) 55 (5.8) 28 (5.3) 19 (6.5)
Arthralgia 102 (5.4) 61 (6.4) 28 (5.3) 12 (4.1)
Back pain 103 (5.5) 60 (6.3) 21 (4.0) 13 (4.5)
Headache 91 (4.9) 54 (5.7) 33 (6.2) 15 (5.1)
Urinary tract infection 103 (5.5) 59 (6.2) 10 (1.9) 13 (4.5)
Bronchitis 93 (5.0) 50 (5.3) 18 (3.4) 14 (4.8)
Diarrhea 100 (5.3) 50 (5.3) 20 (3.8) 10 (3.4)
Myalgia 90 (4.8) 34 (3.6) 27 (5.1) 14 (4.8)
Hypertension 70 (3.7) 39 (4.1) 33 (6.2) 15 (5.1)
Dizziness 57 (3.0) 38 (4.0) 31 (5.8) 21 (7.2)
Accidental overdose 21 (1.1) 14 (1.5) 48 (9.0) 20 (6.8)
SAE, serious adverse event; TEAE, treatment-emergent adverse event.
Supplementary Figure 1 Mean concentrations of alirocumab, free PCSK9 and LDL-C over time in patients with HeFH receiving alir-
ocumab 75/150 mg Q2W with background statin (FH I). HeFH, heterozygous familial hypercholesterolemia; LDL-C, low-density lipopro-
tein cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9; Q2W, every 2 wk; SE, standard error.
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Supplementary Figure 2 Free and total PCSK9 concentrations
after treatment with (A) alirocumab 75/150 mg Q2W (MONO; no
background statin), (B) alirocumab 75/150 mg Q2W (COMBO II;
background statin), and (C) alirocumab 150 mg Q2W (LONG
TERM; background statin) (alirocumab-treated patients).
Follow-up was at 32 wk in MONO, 112 wk in COMBO II, and
86 wk in LONG TERM. PCSK9, proprotein convertase subtili-
sin/kexin type 9; Q2W, every 2 wk; SE, standard error; F/U,
follow-up.
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Supplementary Figure 3 LDL-C percentage reduction at week 24 according to quartiles of baseline total PCSK9 levels. The interaction
P-values compare quartile 1 with quartile 4. CI, confidence interval; LDL-C, low-density lipoprotein cholesterol; LS, least-squares; PCSK9,
proprotein convertase subtilisin/kexin type 9; SE, standard error.
988.e4 Journal of Clinical Lipidology, Vol 13, No 6, December 2019
Supplementary Figure 4 Effect of alirocumab dose increase from 75 to 150 mg Q2Won mean concentrations of (A) alirocumab, (B) free
PCSK9 and (C) LDL-C over time, in alirocumab-treated patients from the COMBO II study (with background statin) LDL-C, low-density
lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9; Q2W, every 2 wk; SE, standard error.
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Supplementary Figure 5 Effect of alirocumab dose increase from 75 to 150 mg Q2Won mean concentrations of (A) alirocumab, (B) free
PCSK9 and (C) LDL-C over time, in alirocumab-treated patients from the FH I study (with background statin). LDL-C, low-density lipo-
protein cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9; Q2W, every 2 wk; SE, standard error.
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Supplementary Figure 6 Free (A) and total (B) PCSK9 levels
by statin dose intensity in LONG TERM (alirocumab-treated pa-
tients). High-intensity statin was defined as atorvastatin 40 to
80 mg or rosuvastatin 20 to 40 mg daily. PCSK9, proprotein con-
vertase subtilisin/kexin type 9; SE, standard error.
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Supplementary Figure 7 Free (A) and total (B) PCSK9 levels by statin dose intensity in COMBO II (alirocumab-treated patients). High-
intensity statin was defined as atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg daily. PCSK9, proprotein convertase subtilisin/kexin
type 9; SE, standard error.
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Supplementary Figure 8 Free (A) and total (B) PCSK9 levels by statin dose intensity in FH I (alirocumab-treated patients). High-
intensity statin was defined as atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg daily. PCSK9, proprotein convertase subtilisin/kexin
type 9; SE, standard error.
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Supplementary Figure 9 LDL-C percentage reduction at week 24 according to statin dose intensity. High-intensity statin was defined as
atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg daily. LDL-C, low-density lipoprotein cholesterol; LS, least squares; SE, standard
error.
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